What is the share price of Transgene Biotek Ltd (TRABI) today?
The share price of TRABI as on 19th June 2025 is ₹4.14. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Transgene Biotek Ltd (TRABI) share?
The past returns of Transgene Biotek Ltd (TRABI) share are- Past 1 week: 4.88%
- Past 1 month: -1.15%
- Past 3 months: 12.83%
- Past 6 months: -42.82%
- Past 1 year: -52.64%
- Past 3 years: 20.92%
- Past 5 years: -20.08%
What are the peers or stocks similar to Transgene Biotek Ltd (TRABI)?
The peers or stocks similar to Transgene Biotek Ltd (TRABI) include:What is the market cap of Transgene Biotek Ltd (TRABI) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Transgene Biotek Ltd (TRABI) is ₹31.97 Cr as of 19th June 2025.What is the 52 week high and low of Transgene Biotek Ltd (TRABI) share?
The 52-week high of Transgene Biotek Ltd (TRABI) is ₹10.84 and the 52-week low is ₹3.22.What is the PE and PB ratio of Transgene Biotek Ltd (TRABI) stock?
The P/E (price-to-earnings) ratio of Transgene Biotek Ltd (TRABI) is -47.72. The P/B (price-to-book) ratio is 2.99.Which sector does Transgene Biotek Ltd (TRABI) belong to?
Transgene Biotek Ltd (TRABI) belongs to the Health Care sector & Biotechnology sub-sector.How to buy Transgene Biotek Ltd (TRABI) shares?
You can directly buy Transgene Biotek Ltd (TRABI) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Transgene Biotek Ltd
TRABI Share Price
4.141.90% (-0.08)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
TRABI Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
TRABI Performance & Key Metrics
TRABI Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -47.02 | 2.99 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 35.65 | 6.55 | 0.84% |
TRABI Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
TRABI Company Profile
Transgene Biotek is a biotechnology company which operates transgene medical centers. Its portfolio of products includes oncology, auto-immunity, drug delivery and biogenerics
BIOCON
PE Ratio
40.44
40.44
1Y Return
4.37%
4.37%
Buy Reco %
71.43
71.43
ONESOURCE
PE Ratio
-1,398.96
-1,398.96
1Y Return
28.36%
28.36%
Buy Reco %
100.00
100.00
SAILIFE
PE Ratio
90.49
90.49
1Y Return
3.43%
3.43%
Buy Reco %
66.67
66.67
ACUTAAS
PE Ratio
57.13
57.13
1Y Return
68.98%
68.98%
Buy Reco %
100.00
100.00
PANACEABIO
PE Ratio
-313.75
-313.75
1Y Return
223.12%
223.12%
Buy Reco %
0.00
0.00
TRABI Forecast
TRABI Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
TRABI
TRABI
Income
Balance Sheet
Cash Flow
Annual Normal View
TRABI Income Statement
TRABI Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.94 | 7.49 | 2.11 | 0.18 | 0.44 | 0.30 | 0.24 | 0.41 | 1.04 | 1.04 | ||||||||||
Raw Materials | 0.00 | 0.03 | 0.03 | 0.01 | 0.06 | -0.05 | 0.07 | 0.00 | 1.38 | 1.39 | ||||||||||
| Power & Fuel Cost | 0.12 | 0.06 | 0.06 | 0.16 | 0.01 | 0.01 | 0.01 | 0.00 | ||||||||||||
| Employee Cost | 0.55 | 0.33 | 0.25 | 0.29 | 0.25 | 0.29 | 0.30 | 0.31 | ||||||||||||
| Selling & Administrative Expenses | 0.20 | 0.25 | 0.35 | 0.37 | 0.27 | 0.27 | 0.27 | 0.48 | ||||||||||||
| Operating & Other expenses | 1.97 | 1.54 | 0.05 | 0.03 | 0.10 | 0.02 | 0.02 | 0.05 | ||||||||||||
EBITDA | -1.90 | 5.28 | 1.37 | -0.68 | -0.25 | -0.24 | -0.43 | -0.43 | -0.34 | -0.35 | ||||||||||
| Depreciation/Amortization | 17.53 | 9.89 | 9.89 | 9.90 | 9.91 | 9.92 | 4.95 | 0.09 | 0.09 | 0.08 | ||||||||||
| PBIT | -19.43 | -4.61 | -8.52 | -10.58 | -10.16 | -10.16 | -5.38 | -0.52 | -0.43 | -0.43 | ||||||||||
| Interest & Other Items | 0.43 | 1.03 | 0.26 | 0.38 | 0.27 | 0.23 | 0.62 | 0.14 | 0.24 | 0.25 | ||||||||||
| PBT | -19.86 | -5.64 | -8.78 | -10.96 | -10.43 | -10.39 | -6.00 | -0.66 | -0.67 | -0.68 | ||||||||||
| Taxes & Other Items | 0.00 | 0.79 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | ||||||||||
| Net Income | -19.86 | -6.43 | -8.78 | -10.96 | -10.43 | -10.39 | -6.00 | -0.66 | -0.67 | -0.68 | ||||||||||
| EPS | -2.62 | -0.85 | -1.16 | -1.45 | -1.38 | -1.37 | -0.79 | -0.09 | -0.09 | -0.09 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
TRABI Company Updates
TRABI Stock Peers
TRABI Past Performance & Peer Comparison
TRABI Past Performance & Peer Comparison
Comparing 3 stocks from
Health CareBiotechnology
Compare valuation on Screener
Health CareBiotechnology
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Transgene Biotek Ltd | -47.72 | 2.99 | — |
| Biocon Ltd | 40.44 | 1.62 | 0.37% |
| Onesource Specialty Pharma Ltd | -1,398.96 | 63.49 | — |
| Sai Life Sciences Ltd | 90.49 | 15.79 | — |
TRABI Stock Price Comparison
Compare TRABI with any stock or ETFCompare TRABI with any stock or ETF
TRABI
TRABI Holdings
TRABI Shareholdings
TRABI Promoter Holdings Trend
TRABI Promoter Holdings Trend
Decreased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has decreased by 1.96%
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
TRABI Institutional Holdings Trend
TRABI Institutional Holdings Trend
Decreased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has decreased by 1.26%
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
TRABI Shareholding Pattern
TRABI Shareholding Pattern
TRABI Shareholding History
TRABI Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing TRABI stock
smallcases containing TRABI stock
Looks like this stock is not in any smallcase yet.
TRABI Events
TRABI Events
TRABI Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
TRABI has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
TRABI Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
TRABI has not given any dividends in last 5 years
TRABI Dividends
TRABI Dividends
Hmm, looks like data is unavailable here. Please come back after some timeTRABI Stock News & Opinions
TRABI Stock News & Opinions
Articles & Videos
Earnings
Transgene Biotek reports consolidated net loss of Rs 0.71 crore in the March 2025 quarter
Net Loss of Transgene Biotek reported to Rs 0.71 crore in the quarter ended March 2025 as against net loss of Rs 0.27 crore during the previous quarter ended March 2024. Sales rose 60.00% to Rs 0.08 crore in the quarter ended March 2025 as against Rs 0.05 crore during the previous quarter ended March 2024. For the full year,net loss reported to Rs 0.68 crore in the year ended March 2025 as against net loss of Rs 0.66 crore during the previous year ended March 2024. Sales rose 13.04% to Rs 0.26 crore in the year ended March 2025 as against Rs 0.23 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales0.080.05 60 0.260.23 13 OPM %-675.00-540.00 --430.77-265.22 - PBDT-0.69-0.25 -176 -0.58-0.56 -4 PBT-0.71-0.27 -163 -0.68-0.66 -3 NP-0.71-0.27 -163 -0.68-0.66 -3 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Transgene Biotek announces board meeting date
Transgene Biotek will hold a meeting of the Board of Directors of the Company on 7 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Transgene Biotek reports consolidated net loss of Rs 0.09 crore in the December 2024 quarter
Net Loss of Transgene Biotek reported to Rs 0.09 crore in the quarter ended December 2024 as against net loss of Rs 0.12 crore during the previous quarter ended December 2023. Sales rose 60.00% to Rs 0.08 crore in the quarter ended December 2024 as against Rs 0.05 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales0.080.05 60 OPM %-112.50-200.00 - PBDT-0.07-0.10 30 PBT-0.09-0.12 25 NP-0.09-0.12 25 Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Transgene Biotek declare Quarterly Result
Transgene Biotek will hold a meeting of the Board of Directors of the Company on 24 January 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Transgene Biotek reports consolidated net loss of Rs 0.07 crore in the September 2024 quarter
Net Loss of Transgene Biotek reported to Rs 0.07 crore in the quarter ended September 2024 as against net loss of Rs 0.13 crore during the previous quarter ended September 2023. Sales rose 20.00% to Rs 0.06 crore in the quarter ended September 2024 as against Rs 0.05 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales0.060.05 20 OPM %-116.67-240.00 - PBDT-0.05-0.11 55 PBT-0.07-0.13 46 NP-0.07-0.13 46 Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Transgene Biotek to announce Quarterly Result
Transgene Biotek will hold a meeting of the Board of Directors of the Company on 12 November 2024Powered by Capital Market - Live
7 months agoCapital Market - Live
Earnings
Transgene Biotek reports consolidated net profit of Rs 0.20 crore in the June 2024 quarter
Net profit of Transgene Biotek reported to Rs 0.20 crore in the quarter ended June 2024 as against net loss of Rs 0.13 crore during the previous quarter ended June 2023. Sales declined 50.00% to Rs 0.05 crore in the quarter ended June 2024 as against Rs 0.10 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales0.050.10 -50 OPM %-820.00-120.00 - PBDT0.22-0.11 LP PBT0.20-0.13 LP NP0.20-0.13 LP Powered by Capital Market - Live
10 months agoCapital Market - Live
Corporate
Transgene Biotek to hold board meeting
Transgene Biotek will hold a meeting of the Board of Directors of the Company on 10 August 2024.Powered by Capital Market - Live
10 months agoCapital Market - Live
Transgene Biotek reports consolidated net loss of Rs 2.60 crore in the September 2021 quarter
3 years agoBusiness Standard
Transgene Biotek reports consolidated net loss of Rs 2.61 crore in the June 2021 quarter
3 years agoBusiness Standard
Over the last 5 years, revenue has grown at a yearly rate of -27.94%, vs industry avg of 19.23%
Over the last 5 years, market share decreased from 0.03% to 0%